在心力衰竭中探索通过阿扎胺的神经激素调节
Midhat Asif1, Fatima Malik2, Abdul Salar Khan3
1Medicine, Khawaja Muhammad Safdar Medical College, Sialkot, PAK.
Cureus
|January 17, 2025
概括
乙胺增强了脱血,并减少了急性心力衰竭 (HF) 中的神经激素的激活. 这种碳酸酶抑制剂通过增加尿路化物分泌和降低宁和阿尔多斯特水平来改善结果.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
背景情况:
- 心力衰竭 (HF) 管理传统上侧重于 (Na) 和水平衡,动脉循环影响排泄.
- 化物 (Cl) 越来越多地被认为是其在HF中的作用,通过斑点密度信号传递影响体积调节和氨酸-氨酸-氨系统 (RAAS) 活性.
- 乙醇胺是一种碳酸胺酶抑制剂,可以通过增加尿路Na和Cl分泌以及循环利尿剂来改善HF的脱血.
研究的目的:
- 在急性心力衰竭 (HF) 患者中研究乙醇胺的神经激素作用.
- 评估阿西塔佐拉米德增强脱血和降低神经激素激活的能力,包括雷宁和阿尔多斯特水平.
- 为了评估RAAS标记物的调制在急性HF.在阿西塔佐胺.
主要方法:
- 一项前性,单中心的观察性研究,涉及80名急性HF患者.
- 两组:病例组 (n=40) 与标准治疗一起接受阿扎胺;对照组 (n=40) 仅接受标准治疗.
- 基线特征,血蛋白活性 (PRA),阿尔多斯特,电解质和临床结果之间的组间比较.
主要成果:
- 乙醇胺组显示尿液中的Cl分泌量显著增加 (p<0.001).
- 与对照组相比,在乙醇胺组中观察到PRA和阿尔多素水平降低 (分别为p=0.002和p=0.006).
- 改善的临床结果包括更多的患者在72小时内无症状 (77.5%对52.5%;p=0.018) 和更短的住院时间 (5.6对7.1天;p=0.028).
结论:
- 乙胺,作为标准治疗的辅助剂,增强脱血和减少神经激素激活在急性HF.
- 这些发现表明,乙醇胺在急性HF的流体管理和RAAS调节方面具有双重益处.
- 需要进一步的研究来确认长期益处,并解决研究的局限性,例如单中心观测设计.
更多相关视频
08:31Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction
Published on: July 26, 2018
10.1K
07:49Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
1.3K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
378
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
378
01:22Heart Failure Drugs: Diuretics
338
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
338
01:26Heart Failure Drugs: Inotropic Agents
511
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
511
01:22Heart Failure Drugs: β-Blockers
314
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
314
01:33Hormonal Regulation
32.9K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.9K
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K